Novartis inks $8.7B AveXis buyout to build gene therapy unit | FierceBiotech
Apr 9, 2018 @ 12:48

Novartis has struck an $8.7 billion deal to buy AveXis. The move sees newly minted Novartis CEO Vas Narasimhan, M.D., pay a hefty premium to establish the company as a frontrunner in the emerging gene therapy sector.

Sourced through from:

Leave a Reply